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An oligonucleotide microarray based on the arrayed-primer extension (APEX) technique has been developed
to simultaneously identify pathogenic fungi frequently isolated from invasive and superficial infections. Spe-
cies-specific oligonucleotide probes complementary to the internal transcribed spacer 1 and 2 (ITS1 and ITS2)
region were designed for 24 species belonging to 10 genera, including Candida species (Candida albicans,
Candida dubliniensis, Candida famata, Candida glabrata, Candida tropicalis, Candida kefyr, Candida krusei,
Candida guilliermondii, Candida lusitaniae, Candida metapsilosis, Candida orthopsilosis, Candida parapsilosis,
and Candida pulcherrima), Cryptococcus neoformans, Aspergillus species (Aspergillus fumigatus and Aspergillus
terreus), Trichophyton species (Trichophyton rubrum and Trichophyton tonsurans), Trichosporon cutaneum, Epi-
dermophyton floccosum, Fusarium solani, Microsporum canis, Penicillium marneffei, and Saccharomyces cerevisiae.
The microarray was tested for its specificity with a panel of reference and blinded clinical isolates. The APEX
technique was proven to be highly discriminative, leading to unequivocal identification of each species,
including the highly related ones C. parapsilosis, C. orthopsilosis, and C. metapsilosis. Because of the satisfactory
basic performance traits obtained, such as reproducibility, specificity, and unambiguous interpretation of the
results, this new system represents a reliable method of potential use in clinical laboratories for parallel
one-shot detection and identification of the most common pathogenic fungi.
The majority of life-threatening fungal infections are caused
by the well-known opportunistic pathogens Candida albicans,
Aspergillus fumigatus, and Cryptococcus neoformans, with the
latter being associated frequently with severe mycoses in AIDS
patients (22, 30). Candidiasis remains the major cause of in-
vasive fungal infections in immunocompromised patients, and
in recent years, an impressive increase in mortality rate due to
candidemia by non-C. albicans Candida species has been noted
(2, 6, 15, 20, 24). It has been suggested that the widespread use
of azoles in clinical settings could have contributed to changing
the etiology of C. albicans candidemia toward non-C. albicans
species, which now account for more than 50% of systemic
Candida infections (2, 6, 15). Rapid diagnosis of these mycoses
is crucial for prompt management of infection with tailored
antifungal treatments. However, conventional laboratory
methods for identification of fungal pathogens, though contin-
uously improving, are still time-consuming and therefore often
inadequate for ensuring early targeted therapy, especially for
uncommon or newly identified fungal species. Unlike what is
currently available for bacteria, molecular approaches for the
identification of pathogenic fungi have been held back so far
due to the lack of a robust sequence data bank. However,
several DNA-based methods have been introduced and have
improved the identification of fungal pathogens and shortened
the time required for their detection (3, 12, 13, 19, 21, 26).
Most molecular procedures allow the identification of one or a
few species at a time (3, 12, 13), thus resulting in a high cost if
all relevant species must be considered. An ideal approach to
overcome this limitation is given by the application of DNA
microarray technology, which may enable discrimination of a
wide range of pathogens in a single assay. The panmicrobial
oligonucleotide array developed by Palacios and colleagues
(23) was designed mainly to produce a staged strategy for
molecular surveillance and discovery of emerging pathogens,
as it covers detection of viruses, bacteria, fungi, and parasites.
However, in the case of fungi, the panmicrobial chip predom-
inantly allows genus identification rather than fungal species
discrimination. It should be noted that rapid identification of
pathogenic fungi at the species level is relevant in medical
practice, as fungemia and other fungal symptomatic infections
are emerging as a leading cause of morbidity and mortality in
the general patient population, especially for hospitalized can-
cer and major surgical patients (15). A DNA microarray spe-
cifically developed by Leinberger and colleagues (18) for de-
tecting fungal pathogens enabled discrimination of the 12 most
common pathogenic Candida and Aspergillus organisms at the
species level, and the array developed by Huang and colleagues
(11) enlarged to 20 the number of identified species, which are
representative of eight different genera. Nevertheless, neither
system encompasses oligonucleotide probes for detection/
identification of emerging fungi increasingly reported to be
responsible for invasive or other symptomatic infections, such
as Candida famata, Candida kefyr, Trichosporon cutaneum,
Fusarium solani, and Penicillium marneffei (5, 10, 24, 31); more-
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over, the probes designed to detect Candida parapsilosis do not
differentiate this species from two newly identified and closely
related ones, i.e., Candida orthopsilosis and Candida metapsi-
losis (27), which were recently reported to cause mycoses in
humans (14, 28). Oligonucleotide probes effectively enabling
simultaneous discrimination of these three species may be use-
ful, since available conventional methods do not allow discrim-
ination of C. parapsilosis from C. orthopsilosis and C. metapsi-
losis (26, 28).
This report describes the development of an up-to-date oligo-
nucleotide array for the unambiguous identification of 24
fungi, allotted into 10 diverse genera, including (i) species
involved in invasive infections and frequently exhibiting a drug-
resistant phenotype, such as Candida glabrata, Candida krusei,
and Aspergillus terreus (17, 24, 25); (ii) emerging fungal patho-
gens, such as C. famata, C. kefyr, Trichosporon cutaneum, or
molds such as Fusarium solani and Penicillium marneffei; and
(iii) the newly defined species C. orthopsilosis and C. metapsi-
TABLE 1. Fungal species tested and oligonucleotides used with the APEX technique
Species GenBankaccession no. Probe Probe sequence
Candida albicans ATCC 10231 X71088 CA1 GGCCCAGCCTGCCGCCAGAGGTCTAAACT
CA2 ACCAATTTTTTATCAACTTGTCACACCAGATTATTAC
Candida dubliniensis CBS 8500 AJ249484 CD1 AAACTTACAACCAAATTTTTTATAAACTTGTCACGAGA
CD2 CCTGCCGCCAGAGGACATAAACTTACAACCAAAT
CD3 CAATACGACTTGGGTTTGCTTGAAAGATGA
CD4 GCTTGACAATGGCTTAGGTGTAACCAAAAACA
Candida famata DSMZ 70590 AB053101 CFA1 CTAGAAATAGTTTGGGCCAGAGGTTTACTGAAC
CFA2 AAACCTTACACACAGTGTTTTTTGTTATTACAAGAAC
Candida glabrata DSMZ 11226 AY208055 CG1 GCTCGGAGAGAGACATCTCTGGGGAGGACCAGTG
CG2 AAAGGAGGTGTTTTATCACACGACTCGACACTTTC
Candida guilliermondii ATCC 6260 L47110 CGU1 TGATACAGAACTCTTGCTTTGGTTTGGCCTAGAGA
CGU2 GGGCCAGAGGTTTAACAAAACACAATTTAATTA
Candida kefyr CBS 1970 L47107 CKE1 AGCTCGTCTCTCCAGTGGACATAAACACAAACAATAT
CKE2 CTCTGCTATCAGTTTTCTATTTCTCATCCTAAACACAA
CKE3 GATTATGAATGAATAGATTGCTGGGGGAATCGTC
CKE4 CAATTCGTGGTAAGCTTGGGTCATAGAGACTCA
Candida krusei ATCC 6258 L47113 CKR1 CGCAGAGTTGGGGGAGCGGAGCGGACGACG
Candida lusitaniae DSMZ 70102 AF172262 CAL1 AAAATTTAATTTTTTTGTTCGCAAAAACAATGTG
CAL2 TGTTGAAAGTTTTGATATTAAGAAATTCGAATAAAAAAA
Candida metapsilosis ATCC 96144 AJ698049 CM1 TAAACTCAACCAAATTTTTATTTAATTGTCAACTTGAT
CM2 TAGGAGAAGGTTGCTTAACTGCAATCCTTTTCTTTC
Candida orthopsilosis ATCC 96139 AJ698048 CO1 CCAGAGATTAAACTCAACCAAATTTTATTTAAGTCAAC
CO2 CGTTGTTGAAAGTTTTGACTATTAGTTAATCAGTTGAC
Candida parapsilosis ATCC 22019 AF287909 CPA1 GAATGAAAAGTGCTTAACTGCATTTTTTCTTACACA
CPA2 GGGGCCTGCCAGAGATTAAACTCAACCAAA
Candida pulcherrima DSMZ 70336 AF235809 CPU1 CACCCTTTTAGGCACAAACTCTAAATCTTAACCG
Canadida tropicalis DSMZ 11953 L47112 CT1 TATTGAACAAATTTCTTTGGTGGCGGGAGCAATCC
CT2 GCAATCCTACCGCCAGAGGTTATAACTAAACCAAACT
Cryptococcus neoformans DSMZ 11959 AY208079 CRN1 GGCACGTTTTACACAAACTTCTAAATGTAATGAATG
Saccharomyces cerevisiae DSMZ 70449 AJ544253 SCE1 CCAAACGGTGAGAGATTTCTGTGCTTTTGTTA
Trichosporon cutaneum CBS 2466 AF444325 TRC1 GTTTCTTAATGGATTGGATTTGGGCGCTGCCAG
Aspergillus fumigatus DSMZ 819 AB051071 AFU1 CTGTTCTGAAAGTATGCAGTCTGAGTTGATTATCG
AFU2 GAAGACCCCAACATGAACGCTGTTCTGAAAG
Aspergillus terreus DSMZ 826 AF078896 AST1 ACCTCCCACCCGTGACTATTGTACCTTGTTGCT
AST2 CCCTGTTCTGAAAGCTTGCAGTCTGAGTGTGA
Epidermophyton floccosum CBS 214.63 AF168130 EPF1 CGAAATCTCCATAGGTGGTTCAGTCTGAGCG
EPF2 TCCCCCTTCTCTCTGAATGCTGGACGGTG
EPF3 ATCCCCCGTTCCACCGGGAGAGGAGAAAGG
Fusarium solani CBS 208.29 AF129105 FSO1 GCCGCAGCTTCCATCGCGTAGTAGCTAACACC
FSO2 GCGGGCACACGCCGTCCCCCAAATACAG
Microsporum canis CBS 113480 AF168127 MCA1 CGGGGAGGTTGCGGGCGGCGAGGGGTGCC
MCA2 CTCGCCGGAGGATTACTCTGGAAAACACACTC
MCA3 TGTGTGATGGACGACCGTCCCCCCTCCCCAG
MCA4 CGTCCCCCCTCCCCAGTAACCACCCACCGC
Penicillium marneffei CBS 334.59 AB049129 PEM1 TGATGAAGATGGACTGTCTGAGTACCATGAAAA
PEM2 CGCCCTGTGAACCCTGATGAAGATGGACTG
PEM3 GAAGCGCCCTGTGAACCCTGATGAAGATGGAC
PEM4 AAGCACGGCTTGTGTGTTGGGTGTGGTCCC
Trichophyton rubrum CBS 286.30 AF168123 TRU1 GACCGACGTTCCATCAGGGGTGAGCAGACG
TRU2 CGCCCGCCGGAGGACAGACACCAAGAAAAAA
TRU3 AGAGCCGTCCGGCGGGCCCCTTCTGGGAGCC
TRU4 CTGTCAGTCTGAGCGTTTAGCAAGCACAATCAG
TRU5 CTAGGCGAATGGGCAGCCAATTCAGCGCCC
Trichophyton tonsurans CBS 120.30 AB166667 TRT1 AGGGCCAAACGTCCGTCAGGGGTGAGCAGATG
TRT2 CAGGATAGGGCCAAACGTCCGTCAGGGG
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losis. The oligonucleotide probes used in this microarray are
complementary to the sequence variation in the internal tran-
scribed spacer 1 and 2 (ITS1 and ITS2) region of each species.
Direct labeling of PCR products is not required, and signals for
fungal species identification are based on the arrayed-primer
extension (APEX) technique, which has been applied success-
fully to discriminate natural variants of human papillomavirus
type 16, to identify germ line mutations in beta-thalassemia,
and for single-nucleotide polymorphism genotyping (4, 7, 8,
16). The specificity and reproducibility of the array were vali-
dated with reference strains, and its application was tested with
blinded clinical isolates.
MATERIALS AND METHODS
Strains. The yeast and mold reference isolates used in this study were obtained
from the American Type Culture Collection (ATCC), Deutsche Sammlung von
Mikroorganismen und Zellkulturen (DSMZ), and Centraalbureau voor Schim-
melcultures (CBS) (Table 1). A selected panel of 20 clinical fungal isolates,
previously identified with conventional laboratory tests (API32 ID and a Vitek 2
advanced colorimetry semiautomated system [bioMerieux, Marcy l’Etoile,
France] for yeast identification and microscopic examination of reproductive
structures for hyphomycetes), were provided by the Unita` Operativa di Micro-
biologia, Ospedale Universitario, Pisa, Italy. The isolates (Table 2) were blindly
submitted to the DNA microarray identification system. All of the isolates were
maintained on Sabouraud agar (yeasts) or potato dextrose agar (molds) (Lio-
filchem S.R.L., TE, Italy) for the duration of the study. Genomic DNAs from
representative bacterial reference strains (Bacillus subtilis ATCC 6633, Esche-
richia coli SCS 110 [ATCC], and Mycobacterium bovis bacillus Calmette-Gue´rin
strain Pasteur [bioMerieux, Lyon, France]) were used as negative controls in
PCR experiments.
Genomic DNA extraction. Genomic DNAs were extracted from yeasts or
molds grown in Sabouraud dextrose broth (yeast) or on potato dextrose agar
(molds) (Liofilchem S.R.L., TE, Italy). DNAs were extracted from yeast samples
as previously described (28). Briefly, yeast cells were harvested in stationary
phase, while mold suspensions were prepared by collecting conidia from 72-h
potato dextrose agar plate colonies washed with 5 ml of 0.1% Tween 20 (Sigma,
St. Louis, MO)–sterile saline. Both yeast and conidia were lysed by vortexing the
pellet for 3 min with 0.3 g glass beads (0.45- to 0.52-mm diameter; Sigma) in 200
l of lysis buffer (100 mM Tris-HCl, pH 8.0, 2% [vol/vol] Triton X-100, 1%
[wt/vol] sodium dodecyl sulfate, and 1 mM EDTA) and 200 l of 1:1 (vol/vol)
phenol-chloroform. After the pellet was vortexed, 200 l of TE (10 mM Tris-
HCl, pH 8.0, 1 mM EDTA) was added to the lysate; the mixture was microcen-
trifuged at full speed for 10 min, and the aqueous phase was transferred to a new
tube. DNA was precipitated by the addition of 1 ml of ethanol. Samples were
centrifuged, and the pellet was suspended in 400 l of TE containing 100 g
RNase (Sigma). The mixture was incubated for 1 h at 37°C and subsequently
treated with proteinase K (5 l of a 20-mg/ml stock solution; Sigma) for 1 h at
65°C and for 30 min at 72°C. Phenol-chloroform treatment was repeated, and
then DNA was precipitated with 1 ml of isopropanol and 10 l of 4 M ammo-
nium acetate, dried, and dissolved in 50 l of TE, pH 8.0.
ITS amplification. The universal fungal primers ITS1 and ITS4 described by
White et al. (29) (Sigma-Genosys, Steinheim, Germany) were used to amplify the
noncoding ITS regions (ITS1 and ITS2) as well as the 5.8S rRNA gene, posi-
tioned between the ITS regions. Reaction mixtures (20 l) contained fungal
DNA (100 ng), 0.4 l primers (5 M), 2 l of deoxynucleoside triphosphate mix
(2 mM dATP, 2 mM dCTP, 2 mM dGTP, 1.7 mM dTTP, and 0.03 mM dUTP),
2 l magnesium-free buffer (10; Solis Biodine, Tartu, Estonia), 2 l MgCl2 (25
mM; Solis Biodine), and 0.2 l Hot Fire DNA polymerase (5 U/l; Solis Bio-
dine). A negative control, which consisted of an equal volume of water replacing
the DNA template, was included in all PCR experiments. Conditions for PCR
amplification were as follows: 94°C for 15 min (hot start); 35 cycles of denatur-
ation at 95°C (1 min), annealing at 56°C (30 s), and elongation at 72°C (75 s); and
a final extension step at 72°C (10 min). Amplified DNA products were separated
by electrophoresis in a 1% agarose gel containing ethidium bromide (0.5 mg/ml);
the running buffer was TAE (40 mM Tris acetate [pH 8.0], 1 mM EDTA). A
100-bp DNA ladder was used as a molecular size marker (Promega). DNA bands
were visualized by UV transillumination. The universal fungal primers used were
tested versus representative bacterial (n  3) and human genomic DNA prep-
arations.
Chip probe design. 5 C-6 aminolinker-modified oligonucleotides (C-6 oligo-
nucleotides) were designed by matching a region of about 35 bp within the ITS1
amplification products to the sequences of ITS deposited in GenBank (http:
//www.ncbi.nlm.nih.gov/entrez/query.fcgi?dbNucleotide&itooltoolbar) (ac-
cession numbers are given in Table 1). Each C-6 oligonucleotide was designed in
order to exclusively add a uracyl (fluorescein-ddUTP) at its 3 end during the
single-base extension reaction. All of the C-6 oligonucleotides were synthesized
by MWG Biotech (Ebersberg, Germany) and spotted onto silanized slides by
Asperbio (Tartu, Estonia), as previously reported (1, 9). Preliminary experiments
were performed by designing a large number of oligonucleotides for each species
in order to test them for the ability to identify and discriminate the 24 fungal
species. Details of the probes used in these experiments are provided in Table 1.
For each fungal species, sets of oligonucleotides were selected among those
previously designed on the basis of their discriminatory power and lack of
cross-reactivity (Table 1).
Purification, hybridization of PCR products on the chip, and signal detection.
PCR products were purified and concentrated using Millipore Y30 columns (7),
and their sizes were reduced by fragmentation to improve hybridization with the
arrayed oligonucleotides. To this end, Y30 column eluate samples (15 l) were
treated with 1 U uracil N-glycosylase (Epicenter Technologies, Madison, WI)
and 1 U shrimp alkaline phosphatase (Amersham Biosciences, Milwaukee, WI),
and the mixtures were incubated at 37°C for 1.5 h and at 95°C for 30 min. At this
temperature, DNA with abasic sites is denatured and fragmented, whereas uracil
N-glycosylase and shrimp alkaline phosphatase are inactivated. Aliquots of the
treated amplicons (9 l) were added to a reaction mixture containing fluores-
cein-ddUTP, cyanine 3-ddATP, ROX-ddCTP, cyanine 5-ddGTP (4  50 pmol),
10 buffer, and 4 U of Thermo Sequenase (Amersham Biosciences, Uppsala,
Sweden) diluted in the provided dilution buffer to give a final volume of 20 l.
Mixtures were quickly placed onto the spotted slide, which was previously
washed with 100 mM NaOH and rinsed with distilled water at 95°C, and incu-
bated at 58°C for 10 min. Slides were washed again with distilled water at 95°C
to remove both traces of nonhybridized PCR products and nonincorporated
labeled dideoxynucleoside triphosphates. A drop of SlowFade Light antifade
reagent (Molecular Probes, Eugene, OR) was then added to prevent signal
fading. Slides were imaged by a Genorama-003 four-color detector (Asper Bio-
tech, Tartu, Estonia). Fluorescence intensities at each position were measured
and converted to base calls according to Genorama image analysis and genotyp-
ing software (Asper Biotech, Tartu, Estonia).
TABLE 2. Selected clinical fungal isolates blindly run to validate
the DNA array-based identification system
Isolate Site of isolation Identification byconventional testsa,b Array identification
b
CF1 Balanopreputial
swab
Candida albicans Candida albicans
CF2 Bronchial
aspirate
Candida tropicalis Candida tropicalis
CF3 Anal swab Candida
guilliermondii
Candida
guilliermondii
CF4 Anal swab Candida glabrata Candida glabrata
CF5 Sputum Candida albicans Candida albicans
CF6 Sputum Candida albicans Candida albicans
CF7 Sputum Candida dubliniensis Candida dubliniensis
CF8 Urine Candida parapsilosis Candida orthopsilosis
CF9 Drainage Candida albicans Candida albicans
CF10 Feces Candida tropicalis Candida tropicalis
CF11 Scalp Microsporum canis Microsporum canis
CF12 Oral swab Candida famata Candida tropicalis
CF13 Feces Candida dubliniensis Candida dubliniensis
CF14 Nail Trichophyton rubrum Trichophyton rubrum
CF15 Bronchial
aspirate
Candida tropicalis Candida tropicalis
CF16 Oral swab Candida glabrata Candida glabrata
CF17 Scalp Trichophyton
tonsurans
Trichophyton
tonsurans
CF18 Vaginal swab Candida parapsilosis Candida metapsilosis
CF19 Blood Candida parapsilosis Candida parapsilosis
CF20 Balanopreputial
swab
Candida lusitaniae Candida lusitaniae
a API32 ID and Vitek 2 advanced colorimetry for yeasts and microscopic
examination of reproductive structures for molds.
b Data in bold show differences between conventional and array identification
results.
VOL. 46, 2008 APEX MICROARRAY FOR IDENTIFICATION OF PATHOGENIC FUNGI 911
 by on M
arch 10, 2008 
jcm.asm.org
D
ow
nloaded from
 
FIG. 1. (A) Representative snapshots from Genorama Basecaller software (Asperbio, Tartu, Estonia), showing the identification of fungal
species by the chip. Cy3 fluorescence images (U channel) show the following identification panels: 1, Candida albicans; 2, C. dubliniensis;
3, C. famata; 4, C. glabrata; 5, C. guilliermondii; 6, C. kefyr; 7, C. krusei; 8, C. lusitaniae; 9, C. metapsilosis; 10, C. orthopsilosis; 11, C.
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Interpretation of results and identification criteria. For species identification,
the following two criteria were required: (i) both APEX probes had to give a
signal and (ii) the extension had to yield a signal on the U channel, as the probes
were designed to extend uridine only. Although A, G, and C signals are not
expected to be incorporated in the APEX reaction, ddA, ddC, and ddG were also
included in the reaction mixture, thus providing a further specificity control to
detect any unspecific extensions. Moreover, to ensure quality control, the fol-
lowing strategies were adopted: (i) DNA samples were randomly processed by
personnel who were blinded to the strain typed, (ii) each APEX oligonucleotide
was spotted in duplicate, and (iii) internal positive controls were included in the
microarray (Fig. 1) to verify that the intensities of the four channels (A, C, U, and
G) were equilibrated.
Confirmation of C. parapsilosis and related species identification by the array.
The two-step DNA-based identification test described by Tavanti et al. (27) was
used to confirm the identification of C. parapsilosis, C. metapsilosis, and C.
orthopsilosis isolates. Briefly, a 716-bp fragment of the SADH (secondary alcohol
dehydrogenase) gene was amplified, purified, and digested with BanI. The dif-
ferent digestion patterns were used to identify the three species, since the C.
parapsilosis, C. metapsilosis, and C. orthopsilosis SADH amplicons contain 1, 3,
and 0 BanI restriction sites, respectively.
RESULTS
Probe design and array setup. An up-to-date DNA microar-
ray system was developed for the unambiguous identification
of 24 fungal species of clinical relevance (Table 1). Oligonu-
cleotides were designed on the basis of the available ITS1
and/or ITS2 sequences (for accession numbers, see Table 1).
The amplicons obtained for each species included the region
carrying ITS1, the 5.8S rRNA gene, and ITS2 and varied in size
from 375 bp (Candida pulcherrima) to 880 bp (Candida gla-
brata) (data not shown). A check test was performed by testing
the specificity of the universal fungal primers used versus bac-
terial (three different strains) and human genomic DNA prep-
arations. No amplification product was detected for any non-
fungal genomic DNA template (data not shown). A pilot study
was undertaken with a redundant number of oligonucleotide
probes in order to evaluate probe reliability, discrimination
power, and lack of cross-reactivity, which would potentially
lead to misinterpretation of the results. The data obtained with
this pilot chip led to an accurate selection of a reduced number
of probes. Sets of C-6 oligonucleotides, ranging from 1 to 5
(Table 1), were proven to unambiguously identify the 24 fungal
species and were used to validate their application for detect-
ing/identifying fungal reference strains and blinded clinical iso-
lates.
Validation of the DNA-based chip with reference strains.
The results presented in Fig. 1 were obtained from experi-
ments repeated at least three times using samples containing
amplicons generated from different preparations of genomic
DNAs of reference species, for a total of 72 slides. As shown in
Fig. 1A, the array system gave an unequivocal response for
each of the 24 reference species considered. The layout of the
chip allows rapid and accurate species identification (Fig. 1B):
most of the species (n  13) were identified by two oligonu-
cleotide probes, replicated twice for a total of four spots, with
the exception of Epidermophyton floccosum, detected with
three replicated probes (Fig. 1A, slide 19); Candida dublinien-
sis, C. kefyr, Penicillium marneffei, and Microsporum canis, de-
tected with a set of four replicated probes (Fig. 1A, slides 2, 6,
21, and 22) for a total of eight spots; and Trichophyton rubrum,
detected with five replicated probes (Fig. 1A, slide 23).
Despite the fact that for five species (Candida krusei, C.
pulcherrima, Cryptococcus neoformans, Saccharomyces cerevi-
siae, and Trichosporon cutaneum) only one probe among the
originally designed probes was found to be suitable for appli-
cation in the final version of the identification array, the results
obtained for these species provided clear and reproducible
identification for each of them (Fig. 1A, slides 7, 12, 14, 15, and
16, respectively). In addition, the microarray was proven to be
highly discriminative, being able to distinguish closely related
species, such as C. orthopsilosis, C. metapsilosis, and C. parap-
silosis as well as Aspergillus fumigatus and A. terreus. As ex-
pected, the results obtained for the “psilosis” complex (Fig.
1A, slides 9 to 11) indicated that a moderate level of cross-
reactivity still exists with the probes used in the final version of
the chip: indeed, when C. metapsilosis (slide 9) or C. orthopsi-
losis (slide 10) was detected by the system, one of the C.
parapsilosis probes (CPA1) (Table 1) gave a simultaneous sig-
nal, whereas when C. parapsilosis was identified, no other
probes produced a positive signal (Fig. 1, slide 11). However,
the low level of cross-reactivity observed within the “psilosis”
species did not prevent their unambiguous identification. As
already observed by Leinberger et al. (18), detection of As-
pergillus fumigatus led to the appearance of a faint signal where
one probe designed for A. terreus was positioned (Fig. 1A, slide
17). This cross-reactivity may be explained by the close genetic
relatedness of these species; nevertheless, it does not prevent
the correct identification of the two Aspergillus species (Fig.
1A, slides 17 and 18). Penicillium marneffei was included in the
panel of fungi identifiable by the system since it has increas-
ingly been associated with opportunistic infections (31) and it
shares morphological traits with the more clinically relevant
organism Aspergillus fumigatus. As shown in Fig. 1A, slide 22,
P. marneffei was clearly identified by eight characteristic spots
(four probes) and did not give any cross-reaction with either A.
fumigatus or A. terreus (Fig. 1A, slides 17 and 18, respectively).
Among the three dermatophyte genera included in the array,
Microsporum canis was identified by a clear and unique signal
(four probes) (Fig. 1A, slide 21), while a weak level of cross-
reactivity was observed, as expected, between the two species
of the Trichophyton genus, i.e., T. rubrum (Fig. 1A, slide 23)
and T. tonsurans (Fig. 1A, slide 24). When the latter species
were present in an independent tested sample, one of the
probes for Epidermophyton floccosum also gave a faint signal
with T. rubrum (Fig. 1A, slides 23 and 24), while E. floccosum
identification (Fig. 1A, slide 19) did not produce any cross-
reactive signal. Therefore, despite the fact that faint aspecific
signals were observed within related species, the identification
parapsilosis; 12, C. pulcherrima; 13, C. tropicalis; 14, Cryptococcus neoformans; 15, Saccharomyces cerevisiae; 16, Trichosporon cutaneum; 17,
Aspergillus fumigatus; 18, A. terreus; 19, Epidermophyton floccosum; 20, Fusarium solani; 21, Microsporum canis; 22, Penicillium marneffei; 23,
Trichophyton rubrum; and 24, T. tonsurans. No signals were detected in the Cy5 channel (i.e., the non-U channel, which was not displayed for
brevity). (B) Layout of chip capture probes (for probe sequences, see Table 1). Control probes are positioned at the corners of each panel.
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of all dermatophytes was clear and unambiguous for any of the
species tested.
Blinded test of a panel of clinical fungal isolates. In separate
experiments, a panel of clinical fungal isolates, including yeasts
and molds, were blindly submitted to the array identification
system. These isolates were previously identified with conven-
tional laboratory tests by the Unita` Operativa di Microbiolo-
gia, Ospedale Universitario, Pisa, Italy. As reported in Table 2,
17 of the isolates were unambiguously identified as the same
species as those obtained by conventional methods (data not
shown). Two clinical isolates identified as Candida parapsilosis
(Table 2) (CF8 and CF18) were detected as C. orthopsilosis
(CF8) and C. metapsilosis (CF18) by the array system. Molec-
ular identification of these two isolates was then performed by
BanI digestion of the SADH amplicon (27), and the digestion
profiles confirmed the results obtained with the array (data not
shown). Isolate CF12, identified as Candida famata (Table 2),
turned out to be C. tropicalis on the basis of the spot position
on the array; the conventional identification was therefore
repeated, confirming that the array identification was indeed
correct and that mislabeling of the isolate plate may have
occurred.
DISCUSSION
This paper describes the setup of an up-to-date version of a
DNA microarray-based system for the identification of the
most common fungal pathogens in humans, encompassing 24
different species belonging to 10 genera. Despite the fact that
a panmicrobial oligonucleotide array was recently proposed for
the diagnosis of infectious diseases (23), it appears to be better
suited for molecular surveillance of infectious agents in high-
throughput/reference laboratories than in small mycology
units. Indeed, the use of the panmicrobial chip may supersede
the effective needs of the local diagnostic routine and may have
high running costs. Moreover, with this array, the use of fungal
probes designed based on the 18S rRNA sequence does not
provide enough discriminatory power to identify each single
species of the 73 fungal genera included in the chip.
The microarray we propose utilizes oligonucleotide probes
complementary to the ITS region (ITS1 or ITS2) of each
species and is based on the APEX technique. The present work
describes the first application of APEX to the field of medical
mycology. The technique proposed here relies both on specific
hybridization between probes and their targets, like conven-
tional microarray-based methods (11, 18, 23), and on the spe-
cific extension of a single base at the 3 side of the anchored
probe. In other words, APEX provides a further level of anal-
ysis and thus, at least theoretically, should give more clear-cut
results and reduced misclassification of fungal species than do
hybridization-only array-based methods.
Optimization of the detection system was a crucial point for
ensuring the reproducibility, specificity, and sensitivity of the
results obtained; in many cases, it was necessary to reduce the
number of probes originally designed and spotted on the pilot
chip (such as those for Candida krusei) due to cross-reaction
among species, which could possibly cause misinterpretation of
results. The optimized microarray detection system was proven
to be highly discriminative, and in its final layout, it allowed the
unequivocal identification of each of the 24 species, including
yeasts and hyphomycetes. Despite a very low level of cross-
reactivity still detectable in the identification of genetically
related species, the signals obtained provided effective discrim-
ination of the “psilosis” group, Aspergillus, and dermatophyte
species tested.
Furthermore, the system was validated by using a selected
panel of clinical fungal isolates previously identified with con-
ventional laboratory tests, which were blindly submitted to the
array identification system. The majority of the isolates were
detected unambiguously in perfect concordance with the re-
sults obtained with the laboratory tests. In two cases, the mi-
croarray resulted in more discriminative results than did con-
ventional biochemical tests, suggesting that this system could
efficaciously flank the diagnostic routine, providing a rapid and
sensitive tool for the identification of closely related species
such as C. orthopsilosis, C. metapsilosis, and C. parapsilosis or
aspergilli.
The chip we have developed is currently used in our clinical
laboratory in parallel with conventional identification proce-
dures. Our aims are both to widen the collection of clinically
significant fungi run with the array system and to confirm its
performance traits, such as reproducibility, specificity, and un-
equivocal interpretation of the results. Indeed, high-through-
put processing of clinical samples will be necessary to validate
the system by testing fungal isolates undergoing selective pres-
sure during the complex interactions occurring within the in-
fected host.
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